Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States
Wilfredo R. Matias, Jacob Koshy, Ellen H. Nagami, Victor Kovac, Letumile R Moeng, Erica S. Shenoy, David C. Hooper, Lawrence C. Madoff, Miriam B. Barshak, Jennifer Johnson, Christopher F. Rowley, Boris Jülg, Elizabeth Hohmann, Jacob E. Lazarus
Abstract
Abstract A large, ongoing multicountry outbreak of human monkeypox has the potential to cause considerable morbidity and mortality. Therapeutics for the treatment of smallpox, a related Orthopoxvirus, may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan-Orthopoxvirus inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.
Topics & Concepts
MonkeypoxOrthopoxvirusMedicineSmallpoxOutbreakVirologyVacciniaVaccinationBiologyBiochemistryGeneRecombinant DNAPoxvirus research and outbreaksBacillus and Francisella bacterial researchHerpesvirus Infections and Treatments